| Name | Title | Contact Details |
|---|
Carl Zeiss Meditec is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mission Canon Medical Systems USA delivers innovative imaging solutions and services through our Made for Life philosophy to improve the quality of life for all people. Our Heritage Canon Medical Systems is born from two global leaders—Canon and Toshiba Medical. In business for more than 100 years` Toshiba Medical was built to improve the quality of life for all people. It delivered on this mission with medical innovations that are Made for Life—made to improve the lives of patients` clinicians and administrators. Its legacy was built with pioneering medical technology` such as the world`s first X-ray machines in 1932 and Japan`s first Magnetic Resonance Imaging systems (MRI) in 1983. Toshiba Medical`s vision was strengthened in 2016 with its acquisition by Canon. Canon entered the healthcare business in 1940 with the development of Japan`s first indirect X-ray camera which was used for the early detection of pulmonary tuberculosis. The partnership of these two companies (now Canon Medical Systems Corporation)` brings together two cutting-edge technology businesses` founded with similar values of creativity` flexibility and patient-friendly healthcare solutions. Today` their combined history of research and innovation drive forward Canon Medical Systems` vision for building a world-class healthcare enterprise.
Diopsys Inc is a Pine Brook, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ophthalmic Imaging Systems is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.